Haleon plc 6-K, filed Sep 5, 2025
Haleon plc (HLN)
6-K
2025-09-05
For: 2025-09-05
View Original
Added on
April 05, 2026
About this 6-K
Haleon plc filed this 6-K on September 5, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September
2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
05
September 2025 - “Director/PDMR
Shareholding”
|
99.1
Haleon
plc: Director/PDMR
Shareholding
5 September 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
This notification sets out the details of the grant of Haleon share
awards over Ordinary Shares and American Depositary Shares (ADS)
made to PDMRs under the Haleon Share Value Plan and Performance
Share Plan.
The Performance Share Plan (Interim) awards are subject to
continued employment and performance conditions over the
performance period ending on 31 December 2027 (vesting in March
2028). Performance targets were disclosed in the Annual Report and
Form 20-F 2024.
The Share Value Plan (Buyout) awards are subject to continued
employment.
All awards were made in line with the principles of Haleon's
Directors' Remuneration Policy and are
subject to malus and clawback provisions.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|||
|
a)
|
Name
|
Carl
Haney
|
||
|
2
|
Reason for the notification
|
|||
|
a)
|
Position/status
|
Chief
R&D Officer
|
||
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|||
|
a)
|
Name
|
Haleon
plc
|
||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Ordinary Shares of £0.01 each
GB00BMX86B70
|
||
|
b)
|
Nature of the transaction
|
(i) Grant
of a conditional award under the Haleon plc Performance Share Plan
(Interim)
(ii) Grant
of a conditional award under the Haleon plc Share Value Plan
(Buyout)
|
||
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
(i)
|
Nil
|
641,096
|
||
|
(ii)
|
Nil
|
192,571
|
||
|
d)
|
Aggregated information
-
Aggregated volume
- Price
|
833,667
Nil
|
||
|
e)
|
Date of the transaction
|
4
September 2025
|
||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|||
|
a)
|
Name
|
Nathalie Gerschtein
|
||
|
2
|
Reason for the notification
|
|||
|
a)
|
Position/status
|
President
North America
|
||
|
b)
|
Initial notification /Amendment
|
Initial
Notification
|
||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|||
|
a)
|
Name
|
Haleon
plc
|
||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|||
|
a)
|
Description of the financial instrument, type of
instrument
Identification
code
|
Haleon plc American Depositary Shares (ADS)
US4055521003
|
||
|
b)
|
Nature of the transaction
|
(i) Grant
of a conditional award under the Haleon plc Performance Share Plan
(Interim)
(ii) Grant
of a conditional award under the Haleon plc Share Value Plan
(Buyout)
|
||
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
(i)
|
Nil
|
244,400
|
||
|
(ii)
|
Nil
|
405,911
|
||
|
d)
|
Aggregated information
-
Aggregated volume
- Price
|
650,311
Nil
|
||
|
e)
|
Date of the transaction
|
4
September 2025
|
||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: September 05,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|